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A. grandis >25) and measuring the 
size of larval parasites (3). Recently, 
PCR has been used for diagnosis in 
veterinary infections (2,7).
For the patient in our study, 
molecular analysis identified human 
pentastomiasis by using a formalin-
fixed microscope slide that had been 
stored for 7 years. A difference of 2 
nt each was seen when the amplified 
nucleotide sequence was compared 
with database sequences of A. 
agkistrodontis and A. moniliformis. 
However, there is no database entry 
in GenBank for A. grandis, the 
geographically closest Armillifer 
species. Serologic assays have been 
developed for identification of A. 
armillatus (2), but no serum was 
available for retrospective analysis. 
In special settings, such as tropical 
snake farming and pet keeping, 
pentastomiasis may be a public health 
concern (2). However, most infections 
have been linked to consumption of 
undercooked snake meat or other 
snake products (1). 
Most immigrants who were given 
a diagnosis of visceral pentastomiasis 
were from Nigeria or the Congo 
region, and diagnoses were made 
after death. Molecular analysis is 
particularly valuable when only 
autoptic paraffin-embedded patient 
material is available. For industrialized 
countries, where experience in 
morphologic identification of unusual 
parasite species is limited, molecular 
analysis is a valuable diagnostic 
tool. Our case-patient constitutes a 
record of imported Armillifer species 
pentastomiasis to Germany. Because 
of increasing international migration, 
more cases of pentastomiasis are 
likely to be seen.
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Mycobacterium  
kyorinense  
Infection
To the Editor: Mycobacterium 
kyorinense is a nonpigmented, slowly 
growing mycobacterium that was 
initially isolated in 2007 from a patient 
with pneumonia in Japan (1,2). The 
sequences of the 16S rRNA, hsp65, 
and rpoB genes of M. kyorinense 
were closely related to, but different 
from, those of the type strains of M. 
celatum and M. branderi, the 2 most 
phylogenetically related species (1). 
Biochemical tests, such as those 
for arylsulfatase activity, tellurite 
reduction, and heat-stable catalase, 
also distinguish M. kyorinense from 
M. celatum and M. branderi. In our 
initial report, in which this species 
was first recognized, we described 3 
strains isolated from Japanese patients 
(1). Recently, 1 additional case 
was reported in Brazil (3). Here we 
describe 7 newly identified patients 
whose infection may have been caused 
by M. kyorinense.
In reviewing the characteristics of 
these 11 patients (10 from Japan and 
1 from Brazil), we found no apparent 
contacts among them. Nine of the 11 
patients had respiratory infections, 1 
had lymphadenitis, and 1 had arthritis 
(Table). Of these, 9 patients fulfilled 
the criteria for infections of clinical 
significance (4) and were considered 
to harbor infection by M. kyorinense. 
Of the 9 patients with respiratory 
infections, 4 died as a result of the 
infection. These data suggest that 
M. kyorinense belongs to a class of 
nontuberculous mycobacteria that 
are pathogenic for humans and have 
substantial clinical effects.
Among the 10 patients for 
whom precise clinical records were 
available, 7 patients were treated 
with first-line tuberculosis drugs, 
mainly rifampin, isoniazid, and 
ethambutol, but these therapies 
were ineffective for all patients. 
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Six patients received a combination 
of antimicrobial drugs, including 
macrolides and fluoroquinolones, as 
first- or second-line chemotherapy, 
and infection was subdued without 
recurrence in 5 patients. In contrast, 
4 patients with pneumonia who did 
not receive sufficient therapy with 
the latter regimen eventually died of 
infection (3 patients) or breast cancer 
(1 patient).
MICs of various antimicrobial 
drugs for the 9 strains of M. kyorinense 
were determined by the broth 
microdilution method as described 
(1). For most strains, the MICs of 
rifampin, ethambutol, and isoniazid 
were relatively high, and MICs of 
macrolides, aminoglycosides, and 
quinolones were relatively low. 
Notably, MICs of rifampin were 
remarkably high (>32 mg/mL) for all 
tested strains (Table).
Direct sequencing of the 16S 
rRNA gene, performed as previously 
described, revealed that 8 of the 
9 available M. kyorinense isolates 
were identical across the entire 
sequenced interval (1,470 bp). 
The sole exception was the strain 
from Brazil, which showed a 4-bp 
substitution that the other strains did 
not (3). Although the other 8 strains 
had identical 16S rRNA sequences, 
all showed heterogeneity at 9 
positions that had not been observed 
to be heterogeneous in the previous 
investigation (1). This observation 
might reflect the presence of 2 copies 
of the 16S rRNA gene, as has been 
occasionally reported for other 
mycobacterial species, including M. 
celatum (5). Direct sequencing of the 
entire rpoB gene demonstrated that 
all strains had identical sequences 
for this locus. The strains differed 
from the sequence of M. tuberculosis 
at 15 nt within codons 511–533. At 
the amino acid level, these changes 
were synonymous for the 2 species, 
with the exception of amino acid 
residue 531. This residue, Ser531 in 
the M. tuberculosis RpoB protein, 
was replaced by an Asp in M. 
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Table.	Clinical	characteristics	of	patients	infected	with	Mycobacterium kyorinense and	antimicrobial	susceptibility	of	the	organism* 
Characteristic 
Patient/strain	no. 
1† 2‡ 3‡ 4 5 6 7 8 9 10 11§ 
Year	of	diagnosis 2005 2006 2008 2008 2009 2009 2010 2010 2011 2011 2007 
Age,	y 89 64 70 81 50 67 72 48 66 60 26 
Sex M F M M M M M F M M M 
Major infection 
site  
Lung Lung Lung Lung Lymph	
node 
Lung Lung Joint Lung Lung Lung 
Specimen Sputum Sputum Sputum BAL Pus BAL Sputum Pus Sputum Sputum Sputum 
Coexisting	
disease 
COPD Breast	
cancer 
None None MDS None None RA,	SLE None COPD NA 
Country Japan Japan Japan Japan Japan Japan Japan Japan Japan Japan Brazil 
AM	drug	MIC, μg/mL           
 STR 0.25 0.25 0.25 S ND 0.25 0.125 0.5 0.25 0.5 S 
 EMB 4 4 2 R 128 2 1 2 4 4 S 
 KAN 0.5 1 0.25 S ND 0.5 0.5 0.5 0.5 0.5 ND 
 INH 16 16 32 R 2 0.5 8 4 1 4 R 
 RIF 32 32 32 R 32 32 32 32 32 32 R 
 LVX 0.125 0.125 0.03 R 0.25 0.06 0.06 0.125 0.125 0.25 ND 
 CLR 0.03 0.03 0.03 ND 0.03 0.03 ND ND 0.03 0.125 ND 
 AMK 0.5 0.5 0.5 ND 0.5 1 ND 0.5 0.5 0.5 S 
Clinical	efficacy	of	AM drug	combination         
 Efficacious  None None None None CLR,	
RIF,	
LVX,	
AMK 
CLR,	
STR,	
MXF 
None LVX,	
EMB,	
CLR 
RIF,	
CLR,	
LVX 
CLR,	
LVX 
NA 
 Nonefficacious BIP None RFB,	
EMB,	
CLR 
INH,	
EMB,	
RIF 
None RIF,	
EMB,	
CLR,	
RIF,	
AZM,	
LVX 
CLR,	
RIF,	
EMB 
INH,	
RIF,	
EMB 
INH,	
RIF,	
EMB 
RFB,	
EMB 
NA 
Outcome Dead Dead Dead Dead Alive Alive Alive Alive Alive Alive Dead 
*BAL,	bronchoalveolar	lavage;	COPD,	chronic	obstructive	pulmonary	disease;	MDS,	myelodysplastic syndrome;	RA,	rheumatoid	arthritis;	SLE,	systemic	
lupus	erythematosus;	NA,	not	available;	AM,	antimicrobial;	STR,	streptomycin;	S,	sensitive;	ND,	not	done;	EMB,	ethambutol;	R, resistant;	KAN,	
kanamycin;	INH,	isoniazid;	RIF,	rifampin;	LVX,	levofloxacin;	CLR,	clarithromycin;	AMK,	amikacin;	AM,	antimicrobial;	RFB,	rifabutin;	MXF,	moxifloxacin;	
BIP,	biapenem;	AZM,	azithromycin.	 
†Reported in (1,2).	 
‡Reported in (1). 
§Reported	in	(3). 
¶Strains	1–10	(except	for	4):	assayed	by	broth	microdilution	MIC	for	nontuberculosis	mycobacteria	(BrothMIC	NTM;	Kyokuto	Pharmaceutical	Industrial	
Co.,	Ltd.,	Tokyo,	Japan).	Strains	4	and	11:	susceptibility	test	performed	by	using	Vite	Spectrum	SR	(Kyokuto	Pharmaceutical	Industrial	Co.,	Ltd.)	and	
BACTEC	MGIT	960	Mycobacterial	Detection	System	(Becton,	Dickinson	and	Company,	Franklin	Lakes,	NJ,	USA),	respectively;	therefore,	numeric	MIC	
data	were	not	available	for	these	strains. 
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kyorinense. Notably, Ser531 is 
the most frequent location of 
substitutions in rifampin-resistant 
strains of M. tuberculosis (6).
Why M. kyorinense has been 
isolated almost exclusively in Japan is 
not clear. This tendency may be largely 
caused by a reporting bias in Japan. 
However, M. kyorinense may have a 
particular geographic distribution. In 
this context, it is noteworthy that the 
sole strain from Brazil characterized 
in the current study differed slightly in 
16S rRNA sequences from the strains 
isolated in Japan.
It also is notable that the M. 
kyorinense strains isolated so far were 
invariably resistant to rifampin by in 
vitro susceptibility testing. Rifampin 
appeared to have been clinically 
ineffective in most patients, although 
definite efficacy of antimicrobial 
drugs cannot be evaluated by this 
retrospective type of study. Analysis 
of the rpoB gene sequence of M. 
kyorinense revealed the replacement 
of aa 531 when compared to the rpoB 
gene sequence of the M. tuberculosis 
protein. This finding suggests 
that M. kyorinense is inherently 
resistant to rifampin because of 
the structural features of its RpoB 
protein. Amino acid replacement 
at RpoB residue 531 also has been 
reported in other bacterial species 
resistant to rifampin, such as M. 
celatum, Borrelia burgdorferi, and 
Spiroplasma citri (7–9). In any case, 
understanding the intrinsic resistance 
of M. kyorinense to rifampin is 
critical for appropriately treating 
infection by this microorganism. On 
the basis of the results of our study, 
we recommend that a combination of 
fluoroquinolones and macrolides and/
or aminoglycosides be used for the 
initial treatment of infection by M. 
kyorinense in most patients. 
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